Discover Algeria | Press area | Contact  
English Français
Registration
English Français
business-banner

October 13, 2025 | 5 days ago

  • More options

    Share on LinkedIn
    Share on Twitter

Algeria: Saidal and Novo Nordisk sign agreement to develop innovative treatments

The state-owned pharmaceutical group Saidal announced on Monday in Algiers that it had signed a “strategic agreement” with Novo Nordisk Algeria. The agreement aims to strengthen the production and distribution of innovative treatments in Algeria, particularly those for people with diabetes, such as the latest generation of insulins.

Algeria Invest
Legal Notices | Terms of Services
news-detail

Saidal and Novo Nordisk Algeria have signed a strategic agreement to collaborate on the production and distribution of innovative molecules in Algeria. This partnership is based on the transfer of technology and expertise to establish a fully aseptic manufacturing within the country.

Novo Nordisk will contribute its expertise in chronic disease research, including diabetes and obesity, while Saidal will contribute its local industrial experience. The agreement aims to strengthen the country's health sovereignty and ensure Algerian patients have better access to innovative, high-quality treatments.

October 14, 2025 | algeria-logo

  • More options

    Share on LinkedIn
    Share on Twitter
Subscribe to the economic newsletter